BR112013004594A2 - método para a determinação de um conteúdo de antígeno - Google Patents

método para a determinação de um conteúdo de antígeno

Info

Publication number
BR112013004594A2
BR112013004594A2 BR112013004594A BR112013004594A BR112013004594A2 BR 112013004594 A2 BR112013004594 A2 BR 112013004594A2 BR 112013004594 A BR112013004594 A BR 112013004594A BR 112013004594 A BR112013004594 A BR 112013004594A BR 112013004594 A2 BR112013004594 A2 BR 112013004594A2
Authority
BR
Brazil
Prior art keywords
antigen
antigen content
determining
content
determining antigen
Prior art date
Application number
BR112013004594A
Other languages
English (en)
Other versions
BR112013004594B1 (pt
Inventor
Mark Garrett
Martinus Antonius Johannes Thijssen
Michelle Allen
Urs Peter Bruderer
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45722927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013004594(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/875,618 external-priority patent/US8546149B2/en
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of BR112013004594A2 publication Critical patent/BR112013004594A2/pt
Publication of BR112013004594B1 publication Critical patent/BR112013004594B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/30—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

método para a determinação de um contúdo de antígeno. a invenção diz respeito a certos métodos para a determinação de um conteúdo de antígeno de um primeiro antígeno em uma mistura compreendendo dois ou mais antígenos. a invenção também diz respeito a um teste de potência para um antígeno em uma vacina comb inada. o método permite a determinação do conteúdo de antígeno em uma mistura compreendendo adicionalmente anticorpos que são capazes de ligar com o antígeno.
BR112013004594-9A 2010-08-27 2011-08-26 método para a determinação de um conteúdo de antígeno BR112013004594B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US37748510P 2010-08-27 2010-08-27
US61/377485 2010-08-27
US12/875618 2010-09-03
US12/875,618 US8546149B2 (en) 2010-08-27 2010-09-03 Potency test for vaccine formulations
EP10181634 2010-09-29
EP10181634.6 2010-09-29
PCT/EP2011/064702 WO2012025612A1 (en) 2010-08-27 2011-08-26 Potency test for vaccine formulations

Publications (2)

Publication Number Publication Date
BR112013004594A2 true BR112013004594A2 (pt) 2016-08-16
BR112013004594B1 BR112013004594B1 (pt) 2020-07-28

Family

ID=45722927

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013004594-9A BR112013004594B1 (pt) 2010-08-27 2011-08-26 método para a determinação de um conteúdo de antígeno

Country Status (9)

Country Link
EP (1) EP2609428B1 (pt)
JP (2) JP5650327B2 (pt)
CN (1) CN103154737B (pt)
BR (1) BR112013004594B1 (pt)
CA (1) CA2808285C (pt)
DK (1) DK2609428T3 (pt)
ES (1) ES2565347T3 (pt)
HU (1) HUE028877T2 (pt)
WO (1) WO2012025612A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
CN106290887A (zh) * 2016-08-01 2017-01-04 瑞普（保定）生物药业有限公司 一种猪肺炎支原体活菌滴度测定方法
TWI694254B (zh) * 2018-03-26 2020-05-21 國光生物科技股份有限公司 一種定量疫苗成品劑量方法及試組
EP3781946A4 (en) 2018-04-18 2022-01-19 BioMadison, Inc. METHODS FOR DETERMINING VACCINE ACTIVITY
CN112379087B (zh) * 2020-10-21 2022-02-11 中国医学科学院医学生物学研究所 一种应用于新型冠状病毒灭活疫苗的裂解液及抗原解离的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459359A (en) * 1981-11-19 1984-07-10 New York Blood Center, Inc. Sensitive immunoassays of antigens or antibodies sequestered within immune complexes
FR2534486B1 (fr) * 1982-10-15 1987-11-20 Commissariat Energie Atomique Support particulaire greffe en surface, son procede de preparation et adsorbants pour chromatographie d'affinite incorporant ce support, ainsi que leur utilisation, notamment en biologie
US4703001A (en) * 1985-10-23 1987-10-27 Synbiotics, Corporation Immunoassay for the detection of serum analytes using pH dependent chastropic acids
AUPN178995A0 (en) 1995-03-16 1995-04-13 University Of Melbourne, The Antigen composition
KR20010032493A (ko) * 1997-11-26 2001-04-25 아이오와 스테이트 유니버시티 리서치 파운데이션, 인코퍼레이티드 재조합 미코플라스마 히오뉴모니아(Ｍｙｃｏｐｌａｓｍａｈｙｏｐｎｅｕｍｏｎｉａｅ) 백신
CN1110705C (zh) * 1998-06-12 2003-06-04 南京红十字血液中心 酶联免疫吸附elisa反应板的再生方法
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6585981B1 (en) * 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
ATE412426T2 (de) * 2001-07-02 2008-11-15 Pfizer Prod Inc Vakzination in einer dosis mit i mycoplasma hyopneumoniae /i
JP2006311824A (ja) * 2005-05-09 2006-11-16 National Agriculture & Food Research Organization 豚マイコプラズマ肺炎ワクチン
US8263343B2 (en) * 2005-12-22 2012-09-11 Ge Healthcare Bio-Science Ab Preparation of biomolecules
BRPI0708522A2 (pt) * 2006-03-03 2011-05-31 Merial Ltd vacina de mycoplasma hyopneumoniae
CN101583872A (zh) * 2006-09-14 2009-11-18 通用电气健康护理生物科学股份公司 测定待分析物浓度的方法
US20090317423A1 (en) * 2008-01-23 2009-12-24 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
CN101545904A (zh) * 2009-03-06 2009-09-30 江苏省农业科学院 抗猪肺炎支原体SIgA间接ELISA检测方法

Also Published As

Publication number Publication date
BR112013004594B1 (pt) 2020-07-28
JP2013536427A (ja) 2013-09-19
JP6368224B2 (ja) 2018-08-01
DK2609428T3 (en) 2016-05-17
CA2808285C (en) 2016-09-06
JP5650327B2 (ja) 2015-01-07
HUE028877T2 (en) 2017-01-30
EP2609428B1 (en) 2016-02-10
ES2565347T3 (es) 2016-04-04
EP2609428A1 (en) 2013-07-03
CA2808285A1 (en) 2012-03-01
WO2012025612A1 (en) 2012-03-01
CN103154737B (zh) 2015-07-15
CN103154737A (zh) 2013-06-12
JP2015052613A (ja) 2015-03-19

Similar Documents

Publication Publication Date Title
CY1123518T1 (el) Ανθρωπινα αντισωματα enanti-tau
BR112013004594A2 (pt) método para a determinação de um conteúdo de antígeno
MX2022012089A (es) Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, anticuerpos de union a interleucina 8 (il-8) y usos de los mismos.
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
CY1121392T1 (el) Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
EA201291181A1 (ru) Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
BR112017016336A2 (pt) proteínas de ligação icos agonistas?
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
SV2011003924A (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
UY32266A (es) Combinaciones antitumorales que contienen anticuepos que reconocen específicamente la cd38 y la citarabina
EA201890655A1 (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
BR112015012933A2 (pt) proteínas de ligação ao antígeno bcma
BR112013021562A2 (pt) anticorpos para cd70
CR20140585A (es) Proteinas de union a antigeno st2
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
BR112013028779B8 (pt) proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, e, uso de uma composição
CU20180024A7 (es) Moléculas de unión a linfopoyetina estromal tímica (tslp), composiciones farmacéuticas que las contienen y método de producción de las mismas
BR112015014833A2 (pt) anticorpo isolado ou fragmento de ligação de antígeno deste, ácido nucléico isolado, célula hospedeira, método de ensaiar uma amostra de tecido removido de um humano para expressão de pd-l1, estojo, e, composição de anticorpo que compreende uma mistura de moléculas do anticorpo
AR089752A1 (es) Anticuerpos anti-lrp5 y metodos de uso
EA201300256A1 (ru) Антитела к рецептору эпидермального фактора роста-3 (her3)
AR090923A1 (es) Anticuerpos anti-il-23
EP3786183A3 (en) Antigen binding constructs to cd3
AR089178A1 (es) Anticuerpos anti-il-36r

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/08/2011, OBSERVADAS AS CONDICOES LEGAIS.